Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(2)
Other(1)

Detailed Status

unknown1
Withdrawn1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

unknown125%
withdrawn125%
completed125%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

NCT02525861
terminatedphase_2

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

NCT02956122
unknown

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

NCT03172455
withdrawnphase_2

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

NCT03385395

Clinical Trials (4)

Showing 4 of 4 trials
NCT02525861Phase 3

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

Completed
NCT02956122Phase 2

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

Terminated
NCT03172455

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

Unknown
NCT03385395Phase 2

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4